New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Cabotegravir – given the trade name Apretude – can be dosed just six times a year and showed superior results to daily, oral therapy with Gilead's widely used Truvada (emtricitabine and ...

Please report side effects. See the full CMI for further details. 1. What is APRETUDE and what is it used for? APRETUDE contains the active ingredient cabotegravir, which belongs to a group of ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.

People in the EU who need access to pre-exposure prophylaxis (PrEP) for HIV could soon have a new option with fewer doses after the European Commission approved ViiV Healthcare’s Apretude.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

is pleased to announce that Quebec has become the first province to publicly reimburse APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure ...